DLL3

DLL3
Identifiers
Aliases	DLL3, SCDO1, pu, pudgy, delta like canonical Notch ligand 3
External IDs	OMIM: 602768; MGI: 1096877; GeneCards: DLL3
Gene location (Human)
Chr.	Chromosome 19 (human)
End	39,508,481 bp
Gene location (Mouse)
Chr.	Chromosome 7 (mouse)
End	28,001,663 bp
RNA expression pattern
	Top expressed in
	ganglionic eminence; ; gonad; ; testicle; ; ventricular zone; ; nucleus accumbens; ; amygdala; ; anterior cingulate cortex; ; prefrontal cortex; ; hypothalamus; ; putamen;
	Top expressed in
	medial ganglionic eminence; ; seminiferous tubule; ; tail of embryo; ; primitive streak; ; embryo; ; embryo; ; epiblast; ; spermatid; ; morula; ; pars intermedia;
	More reference expression data
	More reference expression data
Gene ontology
Molecular function	Notch binding; calcium ion binding;
Cellular component	integral component of membrane; membrane; plasma membrane;
Biological process	Notch signaling pathway; somitogenesis; multicellular organism development; negative regulation of neurogenesis; cell differentiation; compartment pattern specification; paraxial mesoderm development; tissue development; skeletal system development;
	Sources:Amigo / QuickGO
Orthologs
Databases	NCBI: entry; OMA: entry
	10683
	13389
	ENSG00000090932
	ENSMUSG00000003436
	Q9NYJ7
	O88516
	NM_016941; NM_203486
	NM_007866
	NP_058637; NP_982353
	NP_031892
	Wikidata
View/Edit Human	View/Edit Mouse

Delta-like 3 (Drosophila), also known as DLL3, is a protein which in humans is encoded by the DLL3 gene. Two transcript variants encoding distinct isoforms have been identified for this gene.

Function

This gene encodes a member of the delta protein ligand family. This family functions as Notch ligands that are characterized by a DSL domain, EGF repeats, and a transmembrane domain. Expression of DLL3 is highest in fetal brain. It plays a key role in somitogenesis within the paraxial mesoderm.

Clinical significance

Mutations in this gene cause the autosomal recessive genetic disorder Jarcho-Levin syndrome.

Experimental drugs targeting DLL3 have also been investigated as possible treatments for certain types of lung and neuroendocrine cancer, Tarlatamab and rovalpituzumab tesirine are two prominent examples.

References

1 2 3 GRCh38: Ensembl release 89: ENSG00000090932 – Ensembl, May 2017
1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000003436 – Ensembl, May 2017
↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
↑ Turnpenny PD, Bulman MP, Frayling TM, Abu-Nasra TK, Garrett C, Hattersley AT, Ellard S (July 1999). "A gene for autosomal recessive spondylocostal dysostosis maps to 19q13.1-q13.3". Am. J. Hum. Genet. 65 (1): 175–82. doi:10.1086/302464. PMC 1378088. PMID 10364530.
↑ "DLL3 delta like canonical Notch ligand 3 [ Homo sapiens (human) ]".
↑ Chapman G, Sparrow DB, Kremmer E, Dunwoodie SL (March 2011). "Notch inhibition by the ligand Delta-Like 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis". Human Molecular Genetics. 20 (5): 438–41. doi:10.1093/hmg/ddq529. PMID 21147753.
↑ Bulman MP, Kusumi K, Frayling TM, McKeown C, Garrett C, Lander ES, Krumlauf R, Hattersley AT, Ellard S, Turnpenny PD (April 2000). "Mutations in the human delta homologue, DLL3, cause axial skeletal defects in spondylocostal dysostosis". Nat. Genet. 24 (4): 438–41. doi:10.1038/74307. PMID 10742114. S2CID 9284439.
↑ "Rovalpituzumab tesirine - Stemcentrx - AdisInsight".
↑ Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland B, Torgov M, Williams SA, Foord O, Howard P, Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ (August 2015). "A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo". Sci. Transl. Med. 7 (302): 302. doi:10.1126/scitranslmed.aac9459. PMC 4934375. PMID 26311731.

External links

GeneReviews/NIH/NCBI/UW entry on Spondylocostal Dysostosis, Autosomal Recessive

Turnpenny PD, Bulman MP, Frayling TM, et al. (1999). "A gene for autosomal recessive spondylocostal dysostosis maps to 19q13.1-q13.3". Am. J. Hum. Genet. 65 (1): 175–82. doi:10.1086/302464. PMC 1378088. PMID 10364530.
Bulman MP, Kusumi K, Frayling TM, et al. (2000). "Mutations in the human delta homologue, DLL3, cause axial skeletal defects in spondylocostal dysostosis". Nat. Genet. 24 (4): 438–41. doi:10.1038/74307. PMID 10742114. S2CID 9284439.
Dunwoodie SL, Clements M, Sparrow DB, et al. (2002). "Axial skeletal defects caused by mutation in the spondylocostal dysplasia/pudgy gene Dll3 are associated with disruption of the segmentation clock within the presomitic mesoderm". Development. 129 (7): 1795–806. doi:10.1242/dev.129.7.1795. PMID 11923214. S2CID 7550276.
Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. Bibcode:2002PNAS...9916899M. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
Turnpenny PD, Whittock N, Duncan J, et al. (2003). "Novel mutations in DLL3, a somitogenesis gene encoding a ligand for the Notch signalling pathway, cause a consistent pattern of abnormal vertebral segmentation in spondylocostal dysostosis". J. Med. Genet. 40 (5): 333–9. doi:10.1136/jmg.40.5.333. PMC 1735475. PMID 12746394.
Bonafé L, Giunta C, Gassner M, et al. (2004). "A cluster of autosomal recessive spondylocostal dysostosis caused by three newly identified DLL3 mutations segregating in a small village". Clin. Genet. 64 (1): 28–35. doi:10.1034/j.1399-0004.2003.00085.x. PMID 12791036. S2CID 45791073.
Whittock NV, Ellard S, Duncan J, et al. (2005). "Pseudodominant inheritance of spondylocostal dysostosis type 1 caused by two familial delta-like 3 mutations". Clin. Genet. 66 (1): 67–72. doi:10.1111/j.0009-9163.2004.00272.x. PMID 15200511. S2CID 46448881.
Gerhard DS, Wagner L, Feingold EA, et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
Maisenbacher MK, Han JS, O'brien ML, et al. (2005). "Molecular analysis of congenital scoliosis: a candidate gene approach". Hum. Genet. 116 (5): 416–9. doi:10.1007/s00439-005-1253-8. PMID 15717203. S2CID 21481013.
Otsuki T, Ota T, Nishikawa T, et al. (2007). "Signal sequence and keyword trap in silico for selection of full-length human cDNAs encoding secretion or membrane proteins from oligo-capped cDNA libraries". DNA Res. 12 (2): 117–26. doi:10.1093/dnares/12.2.117. PMID 16303743.

This article on a gene on human chromosome 19 is a stub. You can help Wikipedia by adding missing information.

[refGRCh38Ensembl-1] 1 2 3 GRCh38: Ensembl release 89: ENSG00000090932 – Ensembl, May 2017

[refGRCm38Ensembl-2] 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000003436 – Ensembl, May 2017

[3] "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[4] "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[pmid10364530-5] Turnpenny PD, Bulman MP, Frayling TM, Abu-Nasra TK, Garrett C, Hattersley AT, Ellard S (July 1999). "A gene for autosomal recessive spondylocostal dysostosis maps to 19q13.1-q13.3". Am. J. Hum. Genet. 65 (1): 175–82. doi:10.1086/302464. PMC 1378088. PMID 10364530.

[entrez-6] "DLL3 delta like canonical Notch ligand 3 [ Homo sapiens (human) ]".

[pmid21147753-7] Chapman G, Sparrow DB, Kremmer E, Dunwoodie SL (March 2011). "Notch inhibition by the ligand Delta-Like 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis". Human Molecular Genetics. 20 (5): 438–41. doi:10.1093/hmg/ddq529. PMID 21147753.

[pmid10742114-8] Bulman MP, Kusumi K, Frayling TM, McKeown C, Garrett C, Lander ES, Krumlauf R, Hattersley AT, Ellard S, Turnpenny PD (April 2000). "Mutations in the human delta homologue, DLL3, cause axial skeletal defects in spondylocostal dysostosis". Nat. Genet. 24 (4): 438–41. doi:10.1038/74307. PMID 10742114. S2CID 9284439.

[9] "Rovalpituzumab tesirine - Stemcentrx - AdisInsight".

[pmid_26311731-10] Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland B, Torgov M, Williams SA, Foord O, Howard P, Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ (August 2015). "A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo". Sci. Transl. Med. 7 (302): 302. doi:10.1126/scitranslmed.aac9459. PMC 4934375. PMID 26311731.

v t e Signaling pathway: notch signaling pathway
Receptor on signaling cell	Delta DLL1 DLL3 DLL4
Ligand	Jagged JAG1 JAG2
Receptor on receiving cell	Notch 1 Notch 2 Notch 3 Notch 4

DLL3

Function

Clinical significance

References

External links

Further reading